

MINUTES
UTAH ADVISORY PHARMACY COMPOUNDING EDUCATION COMMITTEE
June 18, 2026 | 9:00 A.M.
ROOM 474, 4th Floor
160 E 300 S Salt Lake City UT
Hybrid Meeting- In Person and Electronic

CONVENED: 9:01 A.M.

ADJOURNED: 10:07 A.M.

DOPL STAFF PRESENT ELECTRONICALLY:

Bureau Manager: Jim Garfield

Investigator: Travis Drebing

Board Secretary: Tina Marshall

COMMITTEE MEMBERS PRESENT ELECTRONICALLY:

Chair: Hali O'Malley, Pharm.D.

Jeremy Olsen, Pharm.D.

Vice Chair: Richard Cox, Pharm.D.

Jim Ruble, Pharm.D.

Robb Dengg, Pharm.D.

Chris Cox, Pharm.D.

COMMITTEE MEMBERS NOT PRESENT:

Adam Taintor, MD

DOPL STAFF NOT PRESENT:

Pharmacy Specialist: Maddy Holt

GUESTS ATTENDED ELECTRONICALLY:

Note: Others may have attended but were not identified.

ADMINISTRATIVE BUSINESS:

CALL MEETING TO ORDER

Dr. Hali O'Malley called the meeting to order at 9:01 A.M.

Read and Approve March 19, 2026 Minutes (Audio 00:03:07)

Dr. Dengg made a motion approving the minutes as written.

Dr. Richard Cox seconded the motion.

The Committee Motion carried.

Dr. Ruble abstained from the vote.

DISCUSSION ITEMS:

INSPECTION FORMS - INVESTIGATIONS (Audio 00:04:52)

Mr. Drebing explained that investigations are still seeing issues with SOPs not being fully updated and a lack of training documentation.

Dr. O'Malley asked if investigations have started using the updated 797 form.

Mr. Drebing stated that they were and it is going better than the 795 form.

Dr. O'Malley asked how the 800 form was coming.

Mr. Drebing explained it is still being updated due to a backlog and staffing changes.

R156-17b-614e(3)(4) *(Audio 00:10:27)*

Dr. O'Malley explained that Dr. Chris Cox and Dr. Richard Cox discussed the language found in R156-17b-614e(3)(4). The language in subsections 3 and 4 could lead to confusion as the committee had decided that antineoplastic drugs needed to comply fully with USP800 and non-antineoplastic drugs had exceptions that the committee had carved out in Rule.

The Committee discussed clarifying the language and removing wording that no longer applies or is duplicated earlier in subsections 3 and 4.

It was decided to keep working on the clarifications of the Rule in small groups and have Committee discussions at future meetings.

**503A BULK DRUG SUBSTANCE LIST – NEW BULK DRUG SUBSTANCES
NOMINATED** *(Audio 00:06:58 and 00:42:33)*

Dr. Chris Cox explained he has received many questions about the Pharmacy Compounding Advisory Committee (PCAC) meeting that will be held on July 23-24, 2026, specifically surrounding peptides, the anticipated outcome of the meeting and if DOPL and investigations will be changing their process in anticipation of the meeting.

Mr. Drebing advised pharmacies not to start doing peptides yet as they are not legal federally yet. The PCAC meeting will review several of the peptides but not all the peptides. If the reviewed peptides are approved by PCAC, the peptides still will have to be approved by the FDA and then become a category one API or bulk compound. Once the peptide is on the bulk one list, then they can legally be compounded.

Dr. O'Malley explained that the docket for the meetings is on the PCAC website, which allows professionals and the public to comment through July 9, 2026. It also provides guidelines on what is required to submit comments.

COMMITTEE MEMBER MAKEUP *(Audio 00:54:03)*

Mr. Garfield explained that R156-17b-203(2) states that the Committee consists of seven members and needs to consist of the following: retail pharmacy, hospital pharmacy, at least one physician and other pharmacy specialties determined pertinent by the Division in collaboration with the Board.

Mr. Garfield stated he would like the Committee's opinion on specialties that they would like the Pharmacy Board to consider when recommending applicants to join the Committee.

The Committee stated they would like the following specialties to be considered: rural hospitals, academic, long-term care and veterinary compounding.

ADJOURNED: Meeting adjourned at 10:07 A.M.

Note: These minutes are not intended to be a verbatim transcript but are intended to record the significant features of the business conducted in this meeting. Discussed items are not necessarily shown in the chronological order they occurred.

Privacy Notice:

This meeting may be recorded. If you attend, join or participate in this meeting, the personal data that you provide, or that is collected from you, is generally classified as a public record pursuant to Utah Code 63G-2-301 of the Government Records Access and Management Act (GRAMA), and may be made available to the public as provided by Utah Code 63G-2-201, except where the meeting is closed under Utah Code 52-4-205.

NEXT SCHEDULED MEETING: September 10, 2026.

2026 Tentative Committee Meeting Scheduled:
December 10

(ss) Hali O'Malley
Chairperson
Advisory Pharmacy Compounding Education
Committee

09/10/2026

Date

(ss) [Signature]
Bureau Manager

09/10/2026

Date